↓ Skip to main content

Dove Medical Press

Adaptation of the European Commission-recommended user testing method to patient medication information leaflets in Japan

Overview of attention for article published in Drug, Healthcare and Patient Safety, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 156)
  • High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

news
1 news outlet
twitter
6 X users
facebook
1 Facebook page

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
27 Mendeley
Title
Adaptation of the European Commission-recommended user testing method to patient medication information leaflets in Japan
Published in
Drug, Healthcare and Patient Safety, June 2017
DOI 10.2147/dhps.s114985
Pubmed ID
Authors

Michiko Yamamoto, Hirohisa Doi, Ken Yamamoto, Kazuhiro Watanabe, Tsugumichi Sato, Machi Suka, Takeo Nakayama, Hiroki Sugimori

Abstract

The safe use of drugs relies on providing accurate drug information to patients. In Japan, patient leaflets called Drug Guide for Patients are officially available; however, their utility has never been verified. This is the first attempt to improve Drug Guide for Patients via user testing in Japan. To test and improve communication of drug information to minimize risk for patients via user testing of the current and revised versions of Drug Guide for Patients, and to demonstrate that this method is effective for improving Drug Guide for Patients in Japan. We prepared current and revised versions of the Drug Guide for Patients and performed user testing via semi-structured interviews with consumers to compare these versions for two guides for Mercazole and Strattera. We evenly divided 54 participants into two groups with similar distributions of sex, age, and literacy level to test the differing versions of the Mercazole guide. Another group of 30 participants were divided evenly to test the versions of the Strattera guide. After completing user testing, the participants evaluated both guides in terms of amount of information, readability, usefulness of information, and layout and appearance. Participants were also asked for their opinions on the leaflets. Response rates were 100% for both Mercazole and Strattera. The revised versions of both Guides were superior or equal to the current versions in terms of accessibility and understandability. The revised version of the Mercazole guide showed better ratings for readability, usefulness of information, and layout (p<0.01) than did the current version, while that for Strattera showed superior readability and layout (p<0.01). User testing was effective for evaluating the utility of Drug Guide for Patients. Additionally, the revised version had superior accessibility and understandability.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 11%
Researcher 3 11%
Student > Postgraduate 3 11%
Student > Master 3 11%
Student > Doctoral Student 2 7%
Other 4 15%
Unknown 9 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 5 19%
Medicine and Dentistry 4 15%
Psychology 3 11%
Mathematics 1 4%
Linguistics 1 4%
Other 4 15%
Unknown 9 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2023.
All research outputs
#2,763,207
of 25,584,565 outputs
Outputs from Drug, Healthcare and Patient Safety
#18
of 156 outputs
Outputs of similar age
#49,658
of 331,010 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#1
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them